retatrutide clinical trial results retatrutide weight loss VisualAbstract: reduces body by 17.5% in patients with obesity New Phase 3 retatrutide data

The most common problems reported (excluding cost) for those currently using GLP1 RAs were Prefer oral medication over injections (patients 56%, physicians 32.6%), Made me feel sick (patients 38.1%, physicians 16.3%), and Did not help lose weight (patients 25.4%, physicians 18%)

On convenience , oral wins decisively

The botanical supply chain efforts for improved visibility (transparency and traceability) into verifiably sustainable production sites around the world is now certificated through the emergence of credible international voluntary sustainability standards (VSS)

Zachary Knight: The Science of Hunger & Medications to Combat Obesity People Mentioned Chris Palmer: Professor of Psychiatry, Harvard Medical School Brian Johnson: Blueprint company founder Charles Brenner: Professor, Department of Diabetes & Cancer Metabolism, City of Hope About this Guest Dr

Levin A, Ahmed SB, Carrero JJ, et al

Available from: Han SH, Ockerman K, Furnas H, Mars P, Klenke A, Ching J, et al (2024) Practice patterns and perspectives of the off-label use of GLP-1 agonists for cosmetic weight loss